A Multicenter Compassionate Use Program of Daclatasvir Plus Sofosbuvir With or Without Ribavirin For The Treatment of HIV/HCV Co-infected Patients From France.

Trial Profile

A Multicenter Compassionate Use Program of Daclatasvir Plus Sofosbuvir With or Without Ribavirin For The Treatment of HIV/HCV Co-infected Patients From France.

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Acronyms ANRS CO-HEPAVIH
  • Most Recent Events

    • 06 Mar 2017 Interim results (n=407) published in the JAIDS.
    • 17 Apr 2016 Interim results (n=93) assessing SVR12 and liver function outcome based on changes in Child-Pugh score at post-treatment week 12 or end of treatment were presented at The International Liver Congress™ 2016.
    • 12 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top